Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Yevgeniya Mykhaylevska

Nurse Practitioner, Psychiatric/Mental Health Saint Louis, MO Nurse Practitioner

NPI 1548974066 CMS profile 11505478

10420 Old Olive Street Rd Ste 205, Saint Louis, MO 63141

Open in the dashboard

General payments

$9,039

261 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yevgeniya Mykhaylevska of Saint Louis, MO is reported in the CMS Open Payments database as having received $9,039 across 261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,560 118
2024 General $4,139 107
2023 General $1,339 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yevgeniya Mykhaylevska
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Yevgeniya Mykhaylevska were reported at $3,560. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Yevgeniya Mykhaylevska Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $166 $54–$482 $132
2022 $0 $195 $66–$559 $149
2023 $1,339 $233 $82–$673 $160
2024 $4,139 $236 $84–$688 $164
2025 $3,560 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Teva Pharmaceuticals USA, Inc. $2,495 88 payments
  2. ITI, Inc. $1,609 47 payments
  3. Vanda Pharmaceuticals Inc. $758 9 payments
  4. E.R. Squibb & Sons, L.L.C. $636 19 payments
  5. AbbVie, Inc. $635 20 payments
  6. Alkermes, Inc. $427 8 payments
  7. Tris Pharma Inc $366 15 payments
  8. Neurocrine Biosciences, Inc. $341 15 payments
  9. Janssen Pharmaceuticals, Inc $257 4 payments
  10. Axsome Therapeutics, Inc. $242 5 payments
  11. Other $1,273 31 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $8,978 259 payments
  2. Education $61 2 payments
Products named General payments · program years 2023–2025
  1. Austedo XR $1,543 51 payments
  2. CAPLYTA Psychiatry $1,004 28 payments
  3. UZEDY $953 37 payments
  4. FANAPT $758 9 payments
  5. CAPLYTA Psychiatry $605 19 payments
  6. VRAYLAR $416 10 payments
  7. INGREZZA $341 15 payments
  8. COBENFY $337 13 payments
  9. LYBALVI $302 7 payments
  10. Dyanavel XR $267 14 payments
  11. Other $4,090 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

869

Median for Nurse Practitioner: 389

Drug cost

$472,596

Median for Nurse Practitioner: $21,885

Branded share of claims

20.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 35 $221,108
Ingrezza Valbenazine Tosylate Brand 32 $196,431
Caplyta Lumateperone Tosylate Brand 11 $20,723
Vraylar Cariprazine Hcl Brand 12 $17,454
Aripiprazole Generic 26 $2,551
Sertraline Hcl Generic 143 $1,690
Buspirone Hcl Generic 120 $1,518
Duloxetine Hcl Generic 43 $1,268
Divalproex Sodium Generic 40 $1,127
Hydroxyzine Hcl Generic 39 $1,062

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$68,556

Medicare's payments for the services billed

Medicare patients

323

Average age 70

Services billed

1,499

167 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 74%
Diabetes 50%
Alzheimer's or dementia 50%
Arthritis 48%
Chronic kidney disease 46%
COPD 37%
Heart failure 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FANAPT
  • Vanda Pharmaceuticals Inc. $758
$758 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $601
$601 35 —
CAPLYTA
  • ITI, Inc. $552
$552 11 —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $495
$495 — —
VRAYLAR
  • AbbVie, Inc. $402
$402 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record